John Kilcoyne

John joined JenaValve in 2019 and is a proven leader in the medical device industry, bringing over 30 years of medical device experience in both start-up organizations and publicly traded companies leading IPO and acquisition strategies.

Throughout his career, John has held several medical device leadership roles. He was the CEO of Endonetics, from 1997 until its acquisition by Medtronic in 2002. From 2002 to 2004, John served as the CEO of Solace Therapeutics. From 2004 until 2010, he was President and CEO at Micrus Endovascular Corporation, leading its IPO efforts in 2005, capturing significant market share and acquisition by Johnson & Johnson in 2010. Before joining JenaValve, John served as the President and CEO of ReVision Optics.

John also serves on the Board of Directors at Cerus Endovascular and CerebroTech Medical Systems; both privately held start-up device medical device companies focused on the treatment of hemorrhagic and diagnosis of ischemic stroke, respectively.

John is a proven leader in the medical device industry. He is a named inventor on more than 20 patents. He has broad and applicable experience leading high-tech medical device emerging growth organizations through market approvals, market access, high growth, and successful strategic transactions, including IPOs and M&A activities.

John received his degree from Cornell University.